Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients
with stage III non-small- cell lung cancer, according to [18F]FDG-PET 18 F]FDG-PET
tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled
phase 2 trial